Werewolf Therapeutics (HOWL) Stock Forecast & Price Target

Werewolf Therapeutics Inc. exhibits strong financial momentum as indicated by the increased Core FFO guidance, now projected at $1.84-$1.88, reflecting a growth rate of 5.1% year-over-year. The company has also demonstrated robust operational performance, achieving 4.3% blended rent growth and a 4.1% expansion in same-store NOI, which signals healthy demand for its offerings. Furthermore, improvements in leasing metrics, including a 100 basis points increase in same-store blended lease pricing, underscore the company's effective management and positive market reception.

Werewolf Therapeutics faces a negative outlook primarily due to changes in fundamental financial metrics that indicate weakening revenue and increased costs. The recent revision to revenue growth guidance, now projecting a limited range of (0.20%)-0.40%, reflects a downward trend in same-store revenues, which decreased by 30 basis points year-over-year. Additionally, rising expenses of 3.8% year-over-year have compounded this issue, leading to a decline in net operating income by 2.6%, signaling financial pressures that could impact the company's stock performance.